BidaskClub upgraded shares of BioTelemetry (NASDAQ:BEAT) from a hold rating to a buy rating in a research report report published on Friday.
A number of other analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of BioTelemetry from a hold rating to a sell rating in a research note on Thursday, February 8th. Dougherty & Co reissued a buy rating and issued a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $43.00.
Shares of BioTelemetry (NASDAQ BEAT) opened at $34.10 on Friday. BioTelemetry has a twelve month low of $23.30 and a twelve month high of $39.20. The company has a market cap of $1,109.32, a P/E ratio of 39.19, a price-to-earnings-growth ratio of 1.68 and a beta of 0.75. The company has a current ratio of 1.77, a quick ratio of 1.66 and a debt-to-equity ratio of 0.80.
Hedge funds and other institutional investors have recently made changes to their positions in the company. First Dallas Securities Inc. purchased a new stake in shares of BioTelemetry in the fourth quarter worth $133,000. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of BioTelemetry in the second quarter worth $212,000. FNY Partners Fund LP increased its stake in shares of BioTelemetry by 74.1% in the third quarter. FNY Partners Fund LP now owns 7,000 shares of the medical research company’s stock worth $231,000 after purchasing an additional 2,980 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in BioTelemetry during the third quarter valued at $232,000. Finally, Premier Asset Management LLC purchased a new position in BioTelemetry during the third quarter valued at $237,000. 87.49% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/3256966/biotelemetry-beat-raised-to-buy-at-bidaskclub.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.